## QIBA Volumetric CT Group 3A Update

Thursday, 30 May 2013 at 11:30 AM CT (GMT-6)

### Call Summary

#### In attendance

<table>
<thead>
<tr>
<th>Maria Athelogou, PhD (Chair)</th>
<th>Paul R. Garrett, MD</th>
<th>Reginald Munden, MD</th>
<th>Joe Koudelik</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hubert Beaumont, PhD</td>
<td>Marios Gavrielides, PhD</td>
<td>Daniel Sullivan, MD</td>
<td>Julie Lisiecki</td>
</tr>
<tr>
<td>Andrew Buckler, MS</td>
<td>Edward D. Helton, PhD</td>
<td>Ying Tang, PhD</td>
<td></td>
</tr>
<tr>
<td>Jovanna Danagoulian, PhD</td>
<td>Rudresh Jarecha, MBBS</td>
<td>Pierre Terve, MS</td>
<td></td>
</tr>
<tr>
<td>Alden Dima, MS</td>
<td>Kjell Johnson, PhD</td>
<td>David F. Wiley, MS, PhD</td>
<td></td>
</tr>
</tbody>
</table>

#### Agenda:

1. Welcome to new participants
   a. Short overview of the clinical challenge
2. Update: Status of the Clinical Challenge
3. Update: Paper status (*Paper from the Pilot and Pivotal Challenge – for publication*)
4. Next steps, Other issues
5. Metrology topics for discussion

#### Action Items:

- RSNA Staff to send final participation reminder on Friday, May 31st stating deadline extended to Monday, June 3rd
  - To date, 10 participants with 12 algorithms have applied
- Data should be in the MM³ format
- Participants are reminded not to use product names in their data report
- Participants will be asked to provide any outstanding items on their applications to receive their anonymous ID for participation
- Manuscript re: the pilot and pivotal studies is now with NIST for review.
  - It has been cleared for publication by the FDA.

#### Timeline for clinical challenge:

- **6/03/2013** - Deadline for participants to submit their completed, signed, PDF participant agreements to RSNA
- **7/15/2013** - Deadline for participants to report their findings to study organizers using anonymous ID

Next call: **Thursday, June 13, 2013 at 11:30 AM CT.**

#### Discussion topics to include:

- Finish uncertainty and variability discussion –
  - (Metrology definitions, umbrella SAP, second 3A study design, appropriate sections of inter-method analysis and test-retest report)